TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as ...
Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol
Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...
A few reasons why the want-to-be cholesterol blockbuster Praluent will not be as much of a "budget buster" as the medicine that cures most hepatitis C patients. From the New York Times (New Drug ...
Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause Praluent treatment effect was observed in patients already receiving other lipid-lowering therapies, ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the United States Court of Appeals for the Federal Circuit upheld the decision by the U.S. District Court for the District of ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicine Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive ...
TARRYTOWN, N.Y. and BRIDGEWATER, N.J., Feb. 11, 2019 /PRNewswire/ -- This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients Beginning in ...
PARIS, July 9 (Reuters) - French drugmaker Sanofi and U.S. partner Regeneron said the results of a late-stage study of their Praluent injection in Japan showed the drug reduced "bad cholesterol" among ...
DEAR DR. ROACH: I am a 66-year-old male diagnosed about 15 years ago with mild coronary artery disease, with some blockages in my peripheral arteries. I was taking the maximum recommended dosage of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results